Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
- 5 December 1985
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 313 (23) , 1485-1492
- https://doi.org/10.1056/nejm198512053132327
Abstract
We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer. This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.This publication has 28 references indexed in Scilit:
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cellsCancer, 1984
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- The In Vitro Generation of Effector Lymphocytes and Their Employment in Tumor ImmunotherapyAdvances in Cancer Research, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.The Journal of Experimental Medicine, 1980
- Passive Immunotherapy of Cancer in Animals and ManPublished by Elsevier ,1977
- MODELS FOR SYNGENEIC ADOPTIVE CHEMOIMMUNOTHERAPY OF MURINE LEUKEMIAS*Annals of the New York Academy of Sciences, 1976
- Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donorsInternational Journal of Cancer, 1972